Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.43 |
| ▸ | TACR2 | P21452 | 13/20 | 0.43 |
| ▸ | TAC3 | Q9UHF0 | 3/20 | 0.42 |
| ▸ | TACR3 | P29371 | 5/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7931924 | 1.00 | TACR1 (0.43) | TACR1TACR2TAC3TACR3LSS | |
| SCHEMBL2796395 | 1.00 | TACR1 (0.43) | TACR1TACR2TAC3TACR3LSS | |
| SCHEMBL2799875 | 0.94 | TACR2 (0.43) | TACR1TACR2TAC3TACR3KCNH2 | |
| SCHEMBL7922127 | 0.94 | TACR2 (0.43) | TACR1TACR2TAC3TACR3KCNH2 | |
| SCHEMBL1937481 | 0.94 | TACR2 (0.43) | TACR1TACR2TAC3TACR3KCNH2 | |
| SCHEMBL7934322 | 0.94 | TACR2 (0.43) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL2800559 | 0.94 | TACR2 (0.43) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL2800563 | 0.94 | TACR2 (0.43) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL1937629 | 0.94 | TACR2 (0.41) | TACR1TACR2TAC3TACR3KCNH2 | |
| SCHEMBL7934200 | 0.93 | TACR3 (0.43) | TACR1TACR2TAC3TACR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293770-B2 | Pyrrolidine derivatives as NK-3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2331500-A1 | PYRROLIDINE N-BENZYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100168088-A1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2010040663-A1 | PYRROLIDINE N-BENZYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168088-A1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | OPRK1, OPRL1, OPRD1 | TACR1 8/4885TACR2 10/4885TAC3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.